1-Scott DL; Wolfen F. and Huizinga TW. Rheumatoid arthritis. Lancet, 376(25), 1094-1108, 2010
2-Russell A; Haraoui B; Keystone E. and Klinkhoff A. Current and emerging therapies for rheumatoid arthritis, with a focus on infliximab: clinical impact on joint damage and cost of care in Canada. Clinical Therapeutics, 23(11), 1824–1838, 2001.
3-Sohc C; Lee A; Qiao Y. et al. Prolonged TNF primes firoblast-like synoviocytes in a gene-specifi manner by altering chromatin. Arthritis Rheum, 67, 86-95. 2015
4-Puren AJ; Fantuzzi G; Gu Y. et al. Interleukin-18 induces IL-8 and IL-1via TNF production from non-CD14+ human blood mononuclear cells. J Clin Invest, 101,711–721, 1998.
5-Walsh D.A. and McWilliams D.F. Mechanisms, impact and management of pain in rheumatoid arthritis. Nature Reviews Rheumatology, 10(10), 581–592, 2014.
6-Deane D. Can rheumatoid arthritis be prevented. Best Practice and Research Clinical Rheumatology, 27(4), 87-92, 2013.
7-Ramiro S; Gaujoux-Viala C; Nam J.L. et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Annals of the Rheumatic Diseases, 73(3), 529-535, 2014.
8-Brennan FM; Chantry D; Jackson A; Maini R. and Feldmann M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet, 2, 244-247, 1989
9-Feldmann M. and Maini RN. Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med, 9, 1245-1250, 2003.
10-Schiff M; Keiserman M; Codding C. et al. Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: Open-label extension of the ATTEST Study. Annals of the Rheumatic Diseases. 70 (11), 2003-2007, 2011.
11-Roll P; Palanichamy A; Kneitz C; Dorner T. and Tony H.P. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis & Rheumatology, 54(8):2377-2386, 2006.
12-Barber R; Baillie GS; Bergmann R; Shepherd MC; Sepper R; Houslay MD. and Heeke GV. Differential expression of PDE4 -phosphodiesterase, isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers. Am J Physiol Lung Cell Mol Physiol, 287(2), 332-343, 2004.
13-Spina D. PDE4 inhibitors: current status. Br J Pharmacol, 155(3), 308-315, 2008.
14-Essayan DM. Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation. Biochem Pharmacol, 57(9), 965–973, 1999.
15-Barbier A; Navarro J; Breliere J.C. and Roncucci R. Biochemical and Clinical changes in rats with developing adjuvant arthritis. Agents and Actions, 15,103-105, 1984.
16-Carlson RP; Datko LJ; O’Neil-Davis L; Blazek EM, Delustro F; Beideman R. and Lewis AJ. Comparison of inflammatory changes in established type II collagen and adjuvant induced arthritis using arthritis using outbred Wistar rats. Int. J. Immunopharmacol, 7(6), 811-826, 1985.
17-Flecknell P.A. Laboratory animal anaesthesia, Academic press,London. 1987.
18-Kawamatawong T. Roles of roflumilast, a selective phosphor-diesterase 4 inhibitor, in airway diseases. Thorac. Dis. 9(4), 1144-1154, 2017.
19-Bodor J. and Habener JF. Role of transcriptional repressor ICER in cyclic AMP-mediated attenuation of cytokine gene expression in human thymocytes, J Biol Chem, 273(16), 9544-51, 1998.
20-Bodor J; Bopp T; Vaeth M. et al. Cyclic AMP underpins suppression by regulatory T cells. Eur J Immunol, 42(6), 1375-84, 2012.
21-Furst DE; Breedveld FC; Kalden JR. et al. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF {alpha}) blocking agents and interleukin-l receptor antagonist (IL-lra), for the treatment of rheumatic diseases. Ann Rheum Dis, 64(4), 2-14, 2005.
22-Ebert EC; Das KM; Mehta V. and Rezac C. Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-alpha antibodies. Clin Exp Immunol, 154(3), 325-331, 2008.
23-Keystone EC. Tumor necrosis factor-alpha blockade in the treatment of rheumatoid arthritis. Rheum Dis Clin of North Am, 27,427-43, 2001.
24-Mainirn Breedveld FC; Kalden JR. et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor monoclonal antibody combined with low dose weekly methotrexate in rheumatoid arthritis. A rthritis Rheum, 41(9), 1552-563, 1998.
25-Caldenhoven E; Liden J; Wissink S; Van de Stolpe A; Raaijmakers J; Koenderman L. et al. Negative cross‐talk between RelA and the glucocorticoid receptor: a possible mechanism for the anti-inflammatory action of glucocorticoids Mol Endocrinol, 9, 401-12, 1995.
26-Creed TJ; Lee RW; Newcomb PV; di Mambro AJ; Raju M. and Dayan CM. The effects of cytokines on suppression of lymphocyte proliferation by Dexamethasone. Immunol 183,164-71, 2009.
27-Kam JC; Szfler SJ; Surs W; Sher ER. and Leung DYM.Combination of IL-2 and IL-4 reduces glucocorticoid receptor binding ainity and T cell response to Glucocorticoids. J Immunol; 151; 3460-6; 1993.